STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
The partnership — only the latest such deal between a pharma giant and Isomorphic — will join Isomorphic’s proprietary drug design engine and existing wet lab data from Merck, which will handle the preclinical and clinical development, manufacturing, and commercializing of any products.
- … Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel-winning technology that can model how molecules will bind to proteins, are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance,” STAT reports.
- Food and Drug Administration approved a Sanofi drug, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, Reuters writes.
- As for the official mascots, they have finished keeping passersby at bay and are now happily snoozing in their respective corners.
The drug, branded as Infilbray, was approved for adults and children weighing at least 15 kilograms, or about 33 pounds, with type 3 Gaucher disease, a rare inherited disorder that causes fatty substances to build up in the body and brain.
- And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us.
- Continue to STAT+ to read the full story….
- As for us, we are firing up the trusty kettle for another cup of stimulation.
- Our choice today is peppermint, an old standby from our pantry.
- Rise and shine, everyone, another busy day is on the way.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →